NCT04827563

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

Risk Factors for Dyspnea and Cardiotoxicity in Patients With Multiple Myeloma Who Receive Carfilzomib: A Prospective Pilot Study

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 50 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will explore why some multiple myeloma patients who receive carfilzomib (an anti-cancer medication) experience shortness of breath while others do not. The purpose of this research is to gather information on the effectiveness of the EndoPAT device, which is FDA-approved to assess the health of a patient's blood vessels. These assessments will help doctors leading the study determine the reasons why patients may develop shortness of breath (dyspnea) when being treated with carfilzomib and ways to better prevent this shortness of breath.

Conditions

• Multiple Myeloma
• Shortness of Breath
• Dyspnea
• Cardiotoxicity

Interventions

Type	Name	Description
DEVICE	EndoPAT	An FDA approved device to test the health of a patient's blood vessels, which involves putting an oxygen probe on the participant's finger.
DEVICE	Blood Pressure Cuff	A device used to conduct blood pressure monitoring using a home blood pressure cuff that participant wears for 24 hours.
DIAGNOSTIC_TEST	Echocardiogram	A test used to conduct an ultrasound of participant's heart.
OTHER	Quality of Life Assessment	A survey that will be given to participants to report their quality of life and symptoms related to multiple myeloma.
OTHER	Blood Tests	Routinely collected for all participants who begin carfilzomib treatment.

Timeline

• Start date: 2021-03-22
• Primary completion: 2025-09-08
• Completion: 2025-09-08
• First posted: 2021-04-01
• Last updated: 2026-03-04

Locations

1 site across 1 country: United States